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ABSTRACT 
 
THE REEVALUATION OF MIBI AS THE LIGAND OF 99mTc-MIBI 
RADIOPHARMACEUTICAL FOR MYOCARDIAL IMAGING. Methoxy isobutyl 
isonitrile labelled with technetium-99m (99mTc) radionuclide can be used for the evaluation of 
acute myocardial infarction. The 99mTc-MIBI radiopharmaceutical is available in                           
the lyophilized-kit, which is separately packed with its radionuclide. Recently, in                 
CNTMR-BATAN Bandung, 99mTc-MIBI radiopharmaceutical was prepared using MIBI ligand 
synthesized in 1996 as lyophilized-kits having the radiochemical purity less than 90 % and not 
accumulated in the myocardium. It could be caused by several factors, among others were 
technical preparation of lyophilized dry-kit and the quality of MIBI; therefore the reevaluation 
of the ligand for the quality improvement was needed.  Firstly, MIBI ligand was recristallized. 
It was found that MIBI as [Cu(MIBI)4]BF4 salt was a glassy solid with the melting point            
of 98 -99 oC. The infra red analysis showed the presence of spectra vibration at 1085,             
1180 cm-1 and 2180, 2220 cm-1 for –OCH3 and N≡C groups, respectively. The preparation of               
99mTc-MIBI was performed by adding 99mTc radionuclide into new MIBI liquid-kit, then boiled 
in water bath for minimum period of 10 minutes.  The radiochemical purity of 99mTc-MIBI was 
analysed by thin layer chromatographic method using absolute ethanol as a mobile phase.          
The pre-clinical evaluation was observed in Wistar rat and clinical studies were performed in 
volunter using gamma camera. It is revealed that the radiochemical purity of more than 90 % 
i.e. 96.83 ± 1.43 % was still stable until 24 hours storage at room temperature. The stability 
studies of 99mTc-MIBI in human blood plasma showed that in 6 hours, the radiochemical purity 
was decreased to 90.89 ± 2.90 %. Clinical application of 99mTc-MIBI with tomography 
techniques using gamma camera showed the distinct accumulation of radioactivity in the heart. 
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INTRODUCTION 
 
 Over the years, thalium-201 (201Tl) has been the main radionuclide for 
the assessement of myocardial perfusion and the diagnosis of coronary artery 
diseases. However, due to several disadvantages such as unsatisfactory 
nuclide properties, limited availability, high cost and biological redistribution 
in human body, the replacement of 201Tl by an agent based on a more reliable 
isotop has been a long standing goal in nuclear medicine. Recently, several 
99mTc-cationic isonitrile compounds have been developed to dissolve these 
problems. Technetium (99mTc) is chosen because cheap and emitted gamma 
photon of 140 keV that suitable for gamma camera imaging [1]. 
 99mTc-methoxy isobutyl isonitrile (99mTc-MIBI) is one of promising 
99mTc-labeled radiopharmaceutical as myocardial agent [2]. Myocardial 
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perfusion imaging using this radiopharmaceutical can evaluate the ischemic 
condition, due to oxygen demand greater than the local oxygen supply in the 
myocardium especially in patient with acute myocardial infarction. On the 
other hand, 99mTc-MIBI radiopharmaceutical can be used for studying non 
cardiac tissues such as mamae tumours [3], parathyroid and whole                    
body scan [4]. 
 Previous work, MIBI in the form of [Cu(MIBI)4]BF4 salt has been 
synthesized succesfully in laboratory scale at CNTMR-BATAN Bandung [5].  
The investigation was continued with development of formulation of              
99mTc-MIBI [6].  In the clinical application, 99mTc-MIBI radiopharmaceutical 
was utilized in MIBI lyophylized-kit, which is separately packed with its 
radionuclide. The MIBI lyophylized-kit was formulated using an optimal 
condition obtained in previous investigation and 99mTc radionuclide was 
added immediately to lyophylized-kit before used, according to the MIBI 
labelling protocol [6]. 
 Until now, the preparation of MIBI lyophilized-kit still use 
[Cu(MIBI)4]BF4 salt synthesized in 1996 at CNTMR-BATAN Bandung.           
The radiochemical purity of 99mTc-MIBI radiopharmaceutical prepared using 
the MIBI lyophylized-kit was less than 90 %. Meanwhile according to 
Dupont, radiochemical purity requirement for 99mTc-MIBI 
radiopharmaceutical has to be more than 90 % [7]. The decrease of 
radiochemical purity of CNTMR-BATAN Bandung 99mTc-MIBI 
radiopharmaceutical could be caused by several factors, such as              
lyophilized-kit preparation process including cooling, drying, sealing of vial 
for vacuum condition and also type of vial and septa used. The other 
important factor was the stability of [Cu(MIBI)4]BF4 salt ligand, due to it was 
synthesized in 1996. 
 The purpose of this study is to confirm the stability of [Cu(MIBI)4]BF4 
salt by evaluating its physical-chemical characteristic, the preparation of 
MIBI liquid-kit followed by labelling with 99mTc radionuclide. The stability 
of 99mTc-MIBI labeled compound was evaluated during storage in room 
temperature and in-vitro stability test in the human blood plasma at 37oC.  
Pre-clinical study was done in Wistar rat, while the clinical evaluation of 
99mTc-MIBI was conducted to the volunteer  
 
EXPERIMENTAL METHODS 
 
 The materials used were MIBI in the form of [Cu(MIBI)4]BF4 salt 
synthesized by CNTMR-BATAN Bandung, sodium pertechnetate solution 
from 99Mo-99mTc generator (PT Batan Technology). L-cysteine hydrochloride 
monohydrate (Sigma), sodium citrate, mannitol, ethanol, TLC-Al2O3 plate 
(E.Merck), bacteria filter (0.22 µm, Millipore) and animal Wistar rat              
(body weight 160-200 g). 
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 The equipments used were infra red spectrometer, UV spectrometer, 
melting block apparatus, singlechannel analyzer, dose calibrator, thin layer 
chromatography apparatus, animal scanner and gamma camera. 
 
Analysis of MIBI 
 
 Analysis of MIBI was carried out by infra red spectrometer, UV 
spectrometer, melting point apparatus as well as by visual method, including 
the form, colour and odor of [Cu(MIBI)4]BF4 salt. 
 
Labelling with 99mTc radionuclide 
 
 Labelling of MIBI with 99mTc radionuclide was directly performed 
using liquid-kit prepared the same composition as that MIBI lyophylized-kit.  
Five mg of SnCl2.2H2O was dissolved in 0.1 mL of 1N HCl, the final volume 
was adjusted to 5 mL with steril water for injection (SWFI), and the solution 
was then labelled as solution A. Five mg of [Cu(MIBI)4]BF4 salt was added 
into 8 mL of SWFI and stirred until it was completely dissolved.  Then 10 mg 
of L-cysteine hydrochloride monohydrate, 26 mg of sodium citrate and              
200 mg of mannitol were added, and stirred respectively until dissolution and 
then 0.6 mL of solution A was added.  The final volume was adjusted to              
pH 5.5 – 6.0 with 0.1N NaOH/0.1N HCl.  Final volume was adjusted to              
10 mL with SWFI.  One mL of this solution was dispensed in a 10 mL 
borosilicate vial and added 1.0 – 2.0 mL (5 – 10 mCi) of 99mTc generator 
eluate.  The vial was swirled for a few seconds and placed in a boiling water 
bath for minimum period of 10 minutes. 
 
Determination of Radiochemical Purity of 99mTc-MIBI 
 
 Radiochemical purity of 99mTc-MIBI was determined using thin layer 
chromatography method. Two drops of 99mTc-MIBI solution were applied 
side by side on top of a drop of pre-applied absolute ethanol wet spot on 
TLC-Al2O3 strip (1x10 cm). The TLC-strip was developed with absolute 
ethanol in chromatographic chamber.  Each cm of TLC-strip was cut and 
counted in gamma scintillation counter. 
 
Stability Test of 99mTc-MIBI 
 
 After labelling MIBI liquid-kit with 99mTc radionuclide, the solution 
was kept in the lead pot at room temperature.  The radiochemical purity of 
99mTc-MIBI was checked at 0, 6 and 24 hours by TLC-Al2O3 strip according 
to the procedures described earlier. 
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Stability Test of 99mTc-MIBI in Human Blood Plasma in-vitro 
 
 The in-vitro stability of 99mTc-MIBI in human blood plasma was 
determined at 37 oC as described by Steffens [8].  Two hundred and fifty µL 
of 99mTc-MIBI was added into 500 µL of human blood plasma and stirred 
vigorously.  Futhermore it was kept in lead pot at 37 oC then the                      
plasma sample was analyzed by TLC-Al2O3 strip at 0, 2, 4, 6 and 24                
hours incubation. 
 
Pre-clinical Evaluation of 99mTc-MIBI 
 
 The pre-clinical study was conducted in Wistar rat. After labelling 
MIBI liquid-kit with 99mTc radionuclide, 200 µCi in 100-200 µL of                 
99mTc-MIBI was injected into the rat tail vein.  Biodistribution of 99mTc-MIBI 
was determined by animal scanner at 30 minutes after injection. 
 
Clinical Application of 99mTc-MIBI 
 
 Clinical application of 99mTc-MIBI was performed at Nuclear Medicine 
Department, Hasan Sadikin Hospital.  One mL of MIBI liquid-kit was filtered 
throught 0.22 µm Millipore filter into a steril vial and 1-2 mL (20-30 mCi) of 
99mTc from 99Mo-99mTc generator was added. The vial was swirled for a few 
seconds and placed in a boiling water bath for minimum period of 10 minutes 
and was stored at room temperature. One mL (10 – 15 mCi) of 99mTc-MIBI 
was injected intravenously to the volunter at stress condition (after exercise).  
Imaging was performed on gamma camera 1 hour after injection. 
 
RESULTS AND DICUSSION 
 
 Methoxy isobutyl isonitrile is the unstable compound in the liquid form 
with very strong odor and toxic.  Because of that, MIBI has been prepared in 
the stable form of tetra (2-methoxy isobutyl isonitrile) Copper (I) tetra 
fluoroborate, [Cu(MIBI)4]BF4 salt, odorless, non toxic which is suitable for 
lyophilized-kit MIBI formulation. 
 According to [Cu(MIBI)4]BF4 salt has been synthesized at               
BATAN-Bandung in 1996, therefore the various reevaluation on the stability 
of the compound including physical-chemical analysis and visual evaluation 
as well, should be carried out.  The visual testing results showed that MIBI as 
[Cu(MIBI)4]BF4 salt still have a glassy solid form, odorless with the melting 
point of 98 - 99 oC and 99 – 100 oC for MIBI synthesized in 1996 and                
re-crystallized in 2006, respectively. This melting point is different with 
melting point obtained beforehand [5]. 
 [Cu(MIBI)4]BF4 salt was characterized by infra red spectrometer.               
It was found the same spectrum absorption as the previous characterization 
for the specific groups [5, 9], those were at 2220, 2180 cm1 for N≡C group, 
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as well as, at 1180, 1085 cm-1 for methoxy group (-OCH3). The infra-red 
spectrum of [Cu(MIBI)4]BF4 salt was showed in Figure 1.                                     
The characterization test of [Cu(MIBI)4]BF4 salt using ultra violet 
spectrometer showed that both of sample had the maximum absorption at                    
249 nm (Figure 2). 
 
 
 
 
Figure 1. Infra-red spectrum of [Cu(MIBI)4]BF4 salt, synthesized in 
CNTMR-BATAN Bandung. 
 
 
MIBI recrystallized in 2006
249, 0.892
0.74
0.76
0.78
0.8
0.82
0.84
0.86
0.88
0.9
210 220 230 240 250 260
Wave Length (nm)
A
bs
or
ba
nc
e
MIBI recrystallized in 1996
249, 0.892
0.74
0.76
0.78
0.8
0.82
0.84
0.86
0.88
0.9
210 220 230 240 250 260 270
Wave Length (nm)
A
bs
or
ba
nc
e
 
 
Figure 2. UV spectrum of [Cu(MIBI)4]BF4 salt, synthesized in                   
CNTMR-BATAN Bandung. 
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 The decrease of radiochemical purity of 99mTc-MIBI prepared using 
lyophilized-kit could be caused by various factors, such as the stability of 
[Cu(MIBI)4]BF4 salt as a ligand. In order to prove whether the 
Cu(MIBI)4]BF4 salt still could be used or not as a ligand for the preparation 
of 99mTc-MIBI radiopharmaceutical, the labelling with 99mTc radionuclide 
was performed by using the MIBI liquid-kit. The labelling efficiency was 
expressed as the radiochemical purity of 99mTc-MIBI that was determined by 
thin layer chromatography. In this system, 99mTc-MIBI migrated with the 
front of the mobile phase (Rf = 0.9 – 1.0), and the impurity in the form of 
(99mTcO4)- migrated with Rf = 0.25 – 0.5, meanwhile the impurity of 99mTc 
colloid (99mTcO2) was found at the origin of the strip (Rf = 0.00).  Using this 
system, the both labelled compounds having the radiochemical purity more 
than 90 %, those were 95.78 ± 1.08 % and 95.07 ± 1.57 % for MIBI 
synthesized in 1996 and recrystallized in 2006, respectively. Based on these 
results it could be explanied that both Cu(MIBI)4]BF4 salt still fulfill the 
requirements for ligand in the preparation of 99mTc-MIBI 
radiopharmaceuticals. Moreover, it was seen that both 99mTc-MIBI 
radiopharmaceuticals gave the almost same radiochemical purity. The results 
(n = 11) was shown in Figure 3. 
 
80
82
84
86
88
90
92
94
96
98
100
1 2 3 4 5 6 7 8 9 10 11
Experiment Numbers
99
m
Tc
-M
IB
I r
ad
io
ch
em
ic
al
 p
ur
ity
 
(%
)
A B
 
 
Figure 3. Radiochemical purity of 99mTc-MIBI prepared using MIBI                 
liquid-kit. A : MIBI synthesized in 1996 (♦-♦); B : MIBI 
recrystalized in 2006 (-). 
 
 
 From several previous results, it had been reported that the 
radiochemical purity of  99mTc-MIBI prepared using MIBI lyophilized-kit 
were less than 90 %, thus were not fulfill the requirement of the 
  41
radiopaharmaceutical quality. However 99mTc-MIBI that was formulated 
using MIBI liquid-kit gave more than 90 % of radiochemical purity. 
Therefore, the decrease of chemical purity of 99mTc-MIBI prepared by using 
MIBI lyophilized-kit was suspected caused by various factors in the 
lyophilization process, i.e. vacuum condition, refrigeration and drainage.            
The inappropriate couple of vial and septa resulted the vacuum condition was 
difficult to achieved, that could influence the stability of reductor used. 
 99mTc-MIBI could be used as the multidose radiopharmaceuticals, 
therefore, it is important to know the stability during storage at room 
temperature.  In this study, 99mTc-MIBI radiopharmaceutical was stable for at 
least 6 hours after preparation with the average radiochemical purity of              
95.57 ± 1.96 %.  While, 24 hours after preparation, the radiochemical purity 
was still more than 90 %.  The results (n = 5) was shown in Figure 4. 
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Figure 4. Stability of 99mTc-MIBI prepared using MIBI liquid-kit at room 
temperature. 
 
 
 The successful of the clinical use of radiopharmaceutical was also 
based on its stability in blood plasma. In order to know the stability of               
99mTc-MIBI radiopharmaceutical in human body, the in-vitro determination 
of the radiochemical purity in human blood plasma was done at 37oC.                                               
99mTc-MIBI was moderately stable with slow release of labelled compound 
during incubation in blood plasma. It was found that during 6 hours 
incubation at 37 oC, 99mTc-MIBI has 90.80 ± 2.90 % of radiochemical purity 
and 88.53 ± 3.07 % of radiochemical purity was observed after 24 hours 
incubation. The results of 99mTc-MIBI stability in human blood plasma                                               
in-vitro could be seen in Figure 5. 
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Figure 5. Stability in-vitro of 99mTc-MIBI prepared using MIBI liquid-kit in 
human blood plasma at 37 oC. 
 
 Although 99mTc-MIBI fulfill the requirement of the 
radiopharmaceutical, the suitablity for the purpose in nuclear cardiology must 
be tested.  Therefore, in order to know as well as to prove this case, it must be 
supported by biological test. The accumulation of radiopharmaceutical into 
the organ could be monitored with pre-clinical studies in animal using  
animal scanner. The scintigraphic images of 99mTc-MIBI                                    
into  organs  of  Wistar  rat  1  hour  after  injection  was  shown  in  Figure 6.  
 
 
 
Figure 6. Biodistribution of 99mTc-MIBI 30 minutes after injection in Wistar 
rat using animal scanner. 
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The result indicated that 99mTc-MIBI was accumulated in several organs, 
including the heart, liver, kidney and intestines. Topographically, the heart is 
adjacent to the liver and the lungs, so it was rather difficult to visualize the 
results of scintigraphy method using animal scanner. However, generally 
radioactivity in the liver will descend quickly compared with radioactivity 
accumulated in the heart [10]. 
 Moreover, the clinical evaluation of 99mTc-MIBI radiopharmaceutical 
to the normal volunter using gamma camera has been carried out in Hasan 
Sadikin hospital. Figure 7 showed the heart images of 99mTc-MIBI 
radiopharmaceutical in normal volunteer. It was found that 99mTc-MIBI 
radiopharmaceutical was accumulated in the heart with satisfactory results.  
Therefore, this indicates that 99mTc-MIBI could be used clinically for 
myocardial imaging with good quality visualization. 
 
 
 
Figure 7. Heart imaging of 99mTc-MIBI one hour after injection in normal 
volunteer using gamma camera. A : frontal; B : sagital; C : 
transversal. 
 
 
CONCLUSION 
 
 The result of this study indicated that MIBI in the form of 
[Cu(MIBI)4]BF4 salt, both compounds, synthesized in 1996 and recrystallized 
in 2006 still could be used as a ligand for the preparation of 99mTc-MIBI 
radiopharmaceutical.  However, special precaution should be taken during the 
kit preparation process in order to achieve satisfactory labelling (≥ 90 %) for 
further clinical application. 
A 
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